Wells Trecaso Financial Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$1.43M Sell
6,172
-1,767
-22% -$360K 0.68% 39
2025
Q2
$1.47M Sell
7,939
-248
-3% -$46.1K 0.45% 44
2025
Q1
$1.72M Sell
8,187
-396
-5% -$77K 0.57% 40
2024
Q4
$1.53M Sell
8,583
-231
-3% -$42.5K 0.5% 42
2024
Q3
$1.74M Sell
8,814
-532
-6% -$99.3K 0.57% 37
2024
Q2
$1.6M Sell
9,346
-123
-1% -$20.4K 0.55% 38
2024
Q1
$1.72M Sell
9,469
-1,074
-10% -$185K 0.61% 34
2023
Q4
$1.63M Sell
10,543
-500
-5% -$72.9K 0.66% 30
2023
Q3
$1.65M Sell
11,043
-399
-3% -$58.6K 0.73% 31
2023
Q2
$1.54M Sell
11,442
-238
-2% -$34.9K 0.66% 31
2023
Q1
$1.86M Sell
11,680
-648
-5% -$99.1K 0.86% 30
2022
Q4
$1.99M Buy
12,328
+2
+0% +$307 0.99% 29
2022
Q3
$1.65M Sell
12,326
-743
-6% -$107K 0.91% 30
2022
Q2
$2M Sell
13,069
-283
-2% -$43.2K 1.04% 29
2022
Q1
$2.16M Buy
13,352
+124
+0.9% +$18K 0.96% 29
2021
Q4
$1.79M Sell
13,228
-198
-1% -$23.4K 0.78% 30
2021
Q3
$1.45M Sell
13,426
-322
-2% -$36.8K 0.69% 33
2021
Q2
$1.55M Sell
13,748
-123
-0.9% -$13.9K 0.74% 32
2021
Q1
$1.5M Sell
13,871
-1,568
-10% -$168K 0.79% 30
2020
Q4
$1.65M Sell
15,439
-748
-5% -$71.9K 0.92% 29
2020
Q3
$1.42M Sell
16,187
-304
-2% -$28.6K 0.9% 28
2020
Q2
$1.62M Buy
16,491
+862
+6% +$75.9K 1.12% 24
2020
Q1
$1.19M Sell
15,629
-189
-1% -$16.1K 1.06% 27
2019
Q4
$1.4M Sell
15,818
-748
-5% -$62.1K 1.01% 27
2019
Q3
$1.25M Sell
16,566
-68
-0.4% -$4.66K 1% 28
2019
Q2
$1.21M Sell
16,634
-30
-0.2% -$2.36K 0.99% 28
2019
Q1
$1.34M Buy
16,664
+91
+0.5% +$7.45K 1.13% 26
2018
Q4
$1.53M Buy
16,573
+79
+0.5% +$6.95K 1.46% 25
2018
Q3
$1.56M Sell
16,494
-800
-5% -$75.9K 1.29% 24
2018
Q2
$1.6M Sell
17,294
-1,413
-8% -$138K 1.5% 22
2018
Q1
$1.77M Sell
18,707
-20,371
-52% -$2.24M 1.69% 22
2017
Q4
$3.78M Buy
+39,078
New +$3.68M 3.7% 9

Other funds holding ABBV

Wells Trecaso Financial Group's ABBV Position: Q3 2025 in Review

Wells Trecaso Financial Group reduced its AbbVie (ABBV) stake by 22% in Q3 2025, selling an estimated $360K and leaving 6,172 shares worth $1.43M. The position accounts for 0.68% of the portfolio, ranked #39.

Wells Trecaso Financial Group first reported a position in ABBV in Q4 2017 and has held it in 32 quarters since. The position peaked at $3.78M in Q4 2017. 3,907 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Wells Trecaso Financial Group held 6,172 shares of AbbVie worth $1.43M as of Q3 2025.
  • Wells Trecaso Financial Group sold 1,767 AbbVie shares in Q3 2025, an estimated $360K.
  • AbbVie made up 0.68% of Wells Trecaso Financial Group's portfolio in Q3 2025, its #39 holding.
  • Wells Trecaso Financial Group first reported a position in AbbVie in Q4 2017 and has held it in 32 quarters since.
  • Wells Trecaso Financial Group's AbbVie position peaked at $3.78M in Q4 2017.
  • 3,907 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Wells Trecaso Financial Group's 13F filing for Q3 2025, filed 5 Nov 2025.